Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Bahama (PRWEB) May 05, 2015 Okyanos, ... Orthopedic Lifestyle Report today. The study was conducted to ... such as osteoarthritis and sports-related injuries have ... and stiffness was the most prevalent symptom reported at ... such as walking, standing and bending over. Over half ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 With ... Josie's Organics, one of the country's leading organic ... minds of moms across the country. What to ... family recipe box or spend hours browsing Pinterest ... on http://www.josiesorganics.com/recipes . , The new ...
(Date:5/5/2015)... 2015 In the upbeat Moms Helping Moms ... moms to support each other. Parenting is a tough ... makes it so much easier. Mothers talk about how ... less alone and help them realize there’s no perfect parent; ... who are clearly dear friends share that it's just that, ...
(Date:5/5/2015)... May is National Osteoporosis Month, and also marks ... Bone Health . Founded by Charles T. Price, MD, the ... and physicians about the latest advances in bone care, and ... to a study recently published by the Journal of Bone ... osteoporosis and low bone mass. This breaks down to a ...
(Date:5/5/2015)... St.Louis MO (PRWEB) May 05, 2015 ... innovative bar flavors in 2014, Walgreens introduces the Cookies ... By focusing on innovation, Extend Nutrition has continually raised ... achieved a great taste, combined with an unprecedented nutritional ... Building on this success, Extend Nutrition will launch additional ...
Breaking Medicine News(10 mins):Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 2Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 3Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 4Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 2Health News:The Institute for Better Bone Health Observes National Osteoporosis Month, Celebrates Three Years of Promoting Healthy Bones 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4
... in ovarian cancer has provided the most comprehensive and integrated ... Ovarian serous adenocarcinoma tumors from 500 patients were examined by ... reported in the June 30, 2011, issue of Nature ... of ovarian cancer, accounting for about 85 percent of all ...
... (HealthDay News) -- Obesity is a major risk factor ... women, a new study finds. It included more than ... smoked and were followed for 28 years. During that time, ... disease and 487 (27 percent) from cancer. Researchers found ...
... recent study accepted for publication in The Endocrine Society,s ... early, prolonged treatment with the diabetes drug metformin may prevent ... adolescence. PCOS affects 7 to 10 percent of ... of infertility, affecting an estimated 5 to 6 million women ...
... Reporter , TUESDAY, June 28 (HealthDay News) -- A vaccine ... some promise, while another designed to alter insulin production fails, ... results of both studies were slated to be presented Tuesday ... Type 1 diabetes often appears early in life and ...
... are teaming up to offer one of the nation,s ... trucks. Led by the University of Maryland and ... program will target the so-called short-haul "drayage" fleet that ... The effort seeks to double the impact ...
... TUESDAY, June 28 (HealthDay News) -- Mammography screening reduces breast ... according to a new, large-scale Swedish trial. In a ... longest ever -- the researchers found that the benefits of ... In fact, most of the benefits occur more than 10 ...
Cached Medicine News:Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 2Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 3Health News:Obesity a Major Cause of Early Death in Women: Study 2Health News:Diabetes drug may prevent or delay development of polycystic ovary syndrome 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 3Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 2Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 3Health News:Longest Trial Ever Confirms Mammograms' Benefits 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 3
(Date:5/5/2015)... , May 5, 2015  Boehringer Ingelheim Pharmaceuticals, ... company,s respiratory portfolio will be presented at the ... place May 15-20 in Denver ... obstructive pulmonary disease (COPD) and asthma, and on ... COPD. Of the 29 accepted abstracts, 19 are ...
(Date:5/5/2015)... 5, 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: ... randomized, double-blinded, placebo-controlled Phase 2 clinical trial of ... in combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel ... pancreatic cancer who have high serum levels of ... fourth leading cause of cancer death in ...
(Date:5/5/2015)... 5, 2015  InfuSystem Holdings, Inc. (NYSE MKT: INFU), ... services for the U.S. healthcare industry, today announced that ... May 12, 2015 after the market closes. ... investors on Tuesday, May 12, 2015 at 4:30 p.m. ... To participate in this call, please dial in toll-free ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 8Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 9Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 10Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 11Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 12Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 13Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 14Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4
... VIEW, Calif., April 11, 2011 VIVUS, Inc. (NASDAQ: ... 56-week CONQUER study were published in ... safety of investigational drug QNEXA in 2,487 patients across 93 ... provided an in-depth look at weight loss and improvements in ...
... Life-saving Colorado start-up UrgentRx today announced the ... credit card-sized packets are available now at Dahl,s pharmacies, ... first made its powdered medications available across Colorado in ... of UrgentRx Aspirin to Go , UrgentRx ...
Cached Medicine Technology:QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities 2QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities 3QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities 4UrgentRx® Launches Innovative Line of Portable Life-Saving Medications Across Iowa 2UrgentRx® Launches Innovative Line of Portable Life-Saving Medications Across Iowa 3
White Standard Girdle...
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Short Girdle, Mid-thigh, Front Closure...
Male Body Shaper, Front Closure...
Medicine Products: